Taipei, Taiwan — Bio Preventive Medicine Corp. (BPM), a global leader in innovative biomarker discovery and precision diagnostics, announced today its grand participation in the upcoming BIO Asia-Taiwan 2026 Exhibition this July. BPM cordially invites global biotech peers, clinical experts, distribution partners, and health-conscious public to visit its booth and witness the revolutionary milestones in precision medicine.

At the exhibition, BPM will comprehensively showcase DNlite™, its world-leading detection technology for the prognostic management of Diabetic Kidney Disease (DKD). Riding on the momentum of securing international In Vitro Diagnostic (IVD) marketing clearances and the high-profile inclusion of its latest research in the Late-Breaking Abstracts (LBA) at the 86th American Diabetes Association (ADA) Scientific Sessions—the highest caliber of academic recognition—BPM is rapidly accelerating the clinical application and commercial footprint of its technology across global markets.

We look forward to sharing our latest clinical advancements and discussing global commercial licensing opportunities on-site. Meanwhile, visitors can enjoy interactive trivia games with prizes and fresh, on-site egg waffles (egg cakes)—offering a unique blend of scientific insight and delightful hospitality while experiencing the vital power of "Early Diagnosis, Early Treatment" in kidney health protection.

Exhibition Details

• Exhibition Dates: Thursday, July 16 – Sunday, July 19, 2026
• Show Hours: 10:00 AM – 6:00 PM (Closes at 5:00 PM on the final day)
• Venue: 4th Floor, Taipei Nangang Exhibition Center, Hall 1 (TaiNEX 1, 4F)
• BPM Booth Number: L418

Key Highlights

 Highlight 1: Breaking the Blind Spots of Traditional Indices: DNlite™ Captures Silent Renal Injuries 

Conventional screenings rely heavily on serum creatinine (eGFR) and Urinary Albumin-to-Creatinine Ratio (UACR). However, these indices suffer from diagnostic lag and structural blind spots when capturing early-stage parenchymal kidney damage and Non-Albuminuric Diabetic Kidney Disease (NA-DKD). BPM's proprietary DNlite™ (uPTM-FetA) is a groundbreaking, non-invasive urinary biomarker assay that precisely quantifies specific post-translational modification (PTM) fragments of Fetuin-A in urine. Unlike traditional markers that merely measure accumulated structural damage, uPTM-FetA reflects the active microenvironmental stress within the kidneys before irreversible structural damage occurs, identifying high-risk patients during the golden therapeutic window.

 Highlight 2: Large-Scale Clinical Validation Proves DNlite™'s Superior Predictive Power

By conducting an in-depth analysis of data from the CREDENCE trial—a milestone global clinical study involving 2,429 participants that shaped international diabetes treatment guidelines—BPM successfully validated that its novel urinary biomarker, uPTM-FetA, delivers independent predictive capabilities that far surpass traditional tests (UACR and eGFR). DNlite™ effectively pinpoints high-risk, "hidden" patients misclassified by conventional metrics, resolving the critical clinical blind spot of "residual renal risk" in the era of widespread SGLT2 inhibitor adoption.

 Highlight 3: SGLT2i Efficacy Monitoring and "Early Surrogate Endpoints"

Recent prospective longitudinal clinical follow-up data have demonstrated the immense potential of uPTM-FetA as a precise "response indicator" for targeted therapies:

Debunking the "eGFR Dip" Myth： Patients initiating SGLT2i treatment frequently experience a functional eGFR dip in the first 4 weeks due to afferent arteriolar vasoconstriction. DNlite™ observed that the urinary uPTM-FetA/Ucr ratio drops rapidly and significantly during this exact window. This sends a critical molecular signal to clinicians: the renal parenchymal cells are unharmed, and the underlying cellular hypoxia and mitochondrial metabolic stress are being actively relieved.

A 3-Month Golden Window to Predict Long-Term Renal Stability： At month 3 of SGLT2i therapy, the dynamic decline of uPTM-FetA flawlessly predicted long-term eGFR slope trajectories. For drug pipelines and precision medicine, this establishes a vital early surrogate endpoint capable of forecasting structural organ repair in the initial stages of treatment, thereby substantially shortening drug development cycles.

On-Site Booth Activities: Where Knowledge Meets Flavor 

Precision medicine can be engaging and fun! To help the public easily understand the principles and importance of "Early Diagnosis, Early Treatment," we have designed exclusive interactive experiences at our booth: 

 Gamified Trivia with Prizes: Unlock your body's "kidney warning signals" through fun, interactive games and win exquisite gifts upon answering correctly! 

 The Fuel Station: Freshly baked, fragrant egg waffles will be served in limited quantities on-site. Fuel your taste buds and mind simultaneously as you absorb cutting-edge medical insights! (Note: Detailed schedules and participation rules are subject to on-site announcements).

Book a Meeting

To ensure a highly professional and efficient consultation experience, clinical experts and business partners are welcome to schedule one-on-one business meetings with us in advance. Our professional team will be fully at your disposal.

 Contact Email： info@bpmbiotech.com